Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.

ABSTRACT:

Background

The cardiorenal effects of sodium-glucose cotransporter 2 inhibition (empagliflozin 25 mg QD) combined with angiotensin-converting enzyme inhibition (ramipril 10 mg QD) were assessed in this mechanistic study in patients with type 1 diabetes with potential renal hyperfiltration.

Methods

Thirty patients (out of 31 randomized) completed this double-blind, placebo-controlled, crossover trial. Recruitment was stopped early because of an unexpectedly low proportion of patients with hyperfiltration. Measurements were obtained after each of the 6 treatment phases over 19 weeks: (1) baseline without treatment, (2) 4-week run-in with ramipril treatment alone, (3) 4-week combined empagliflozin-ramipril treatment, (4) a 4-week washout, (5) 4-week combined placebo-ramipril tr

SUBMITTER: Lytvyn Y 

PROVIDER: S-EPMC9354594 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature